CSI Takes Reverse Merger Route To Public Market As IPO Options Fade
This article was originally published in The Gray Sheet
Executive Summary
Atherectomy catheter device maker Cardiovascular Systems Inc. will merge with antibiotic drug developer Replidyne for access to the biopharma firm's cash and public shell under a Nov. 4 stock-swap agreement